Dr. Scott Struthers

“This has been another strong quarter of executing our plan to make Crenetics the premier endocrine company. Crenetics is committed to translating the complexities of cutting-edge endocrinology into real value for patients, and with the launch of Palsonify, we are delivering on that commitment every day.”

“We're transitioning from building a pipeline to building a business. In 2025, we successfully launched our first commercial product with a label that reflects its ability to become the preferred medical treatment for acromegaly.”

“Turning to slide 3, we are pleased to provide an update on our corporate progress and share our second quarter results. We continue to execute on our mission to develop innovative therapies for patients with endocrine diseases and endocrine-related tumors.”

“We're pleased to share our first quarter results and highlight the great progress we're making towards our mission of transforming the lives of patients with serious endocrine and endocrine-adjacent diseases.”